Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (1714)	7/11/2003 8:47:54 PM
From: Ian@SI	Respond to of 3044

From Briefing this morning re Business Week... * 06:58 ET Millennium Pharma's recent dip may have been unwarranted -- B-Week (MLNM) 14.51: BusinessWeek article discusses the recent drop in MLNM stock as a buying opportunity. Its recent fall in price coincided with rumors of the company being takeover bait with JNJ as a potential suitor. However, the only announcement with JNJ was its agreement to market its Velcade drug overseas with mixed reviews on the terms of the deal. The editor of "Medical Technology Stock Newsletter" believes the stock can hit 30 in a year in light of its raising the ante by retaining 100% of the U.S. rights on Velcade.